Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F de Groot

Showing results (31-40 of 121) with videos related to

Pageof 13
Sort By:
Molecular Cancer Therapeutics|June 17, 2016
Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma ModelsSoon Young Park, Yuji Piao, Kang Jin Jeong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2014
Antiangiogenic therapy for glioblastoma: current status and future prospectsTracy T Batchelor, David A Reardon, John F de Groot, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 17, 2013
Isotretinoin maintenance therapy for glioblastoma: a retrospective reviewSheree E Chen, Shauna S Choi, Jane E Rogers, et al.
Journal of Neuro-Oncology|March 5, 2008
Knockdown of GluR1 expression by RNA interference inhibits glioma proliferationJohn F de Groot, Yuji Piao, Li Lu, et al.
Neuro-Oncology|January 12, 2021
PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastomaShaofang Wu, Xiaolong Li, Feng Gao, et al.
Neurology. Clinical Practice|August 15, 2018
B lymphoblastic leukemia/lymphoma presenting as seventh cranial nerve palsyCarlos Kamiya-Matsuoka, Pedro Garciarena, Hesham M Amin, et al.
Expert Review of Anticancer Therapy|July 6, 2018
Highlighting the need for reliable clinical trials in glioblastomaJacob J Mandel, Michael Youssef, Ethan Ludmir, et al.
Journal of Neuro-Oncology|June 9, 2016
Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastomaJacob J Mandel, David Cachia, Diane Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2013
Neutrophils promote the malignant glioma phenotype through S100A4Ji Liang, Yuji Piao, Lindsay Holmes, et al.
Neuro-Oncology|February 20, 2010
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and miceJohn F de Groot, Gregory Fuller, Ashok J Kumar, et al.
Pageof 13

Showing results (31-40 of 121) with videos related to

Sort By:
Pageof 13
Molecular Cancer Therapeutics|June 17, 2016
Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma ModelsSoon Young Park, Yuji Piao, Kang Jin Jeong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2014
Antiangiogenic therapy for glioblastoma: current status and future prospectsTracy T Batchelor, David A Reardon, John F de Groot, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 17, 2013
Isotretinoin maintenance therapy for glioblastoma: a retrospective reviewSheree E Chen, Shauna S Choi, Jane E Rogers, et al.
Journal of Neuro-Oncology|March 5, 2008
Knockdown of GluR1 expression by RNA interference inhibits glioma proliferationJohn F de Groot, Yuji Piao, Li Lu, et al.
Neuro-Oncology|January 12, 2021
PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastomaShaofang Wu, Xiaolong Li, Feng Gao, et al.
Neurology. Clinical Practice|August 15, 2018
B lymphoblastic leukemia/lymphoma presenting as seventh cranial nerve palsyCarlos Kamiya-Matsuoka, Pedro Garciarena, Hesham M Amin, et al.
Expert Review of Anticancer Therapy|July 6, 2018
Highlighting the need for reliable clinical trials in glioblastomaJacob J Mandel, Michael Youssef, Ethan Ludmir, et al.
Journal of Neuro-Oncology|June 9, 2016
Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastomaJacob J Mandel, David Cachia, Diane Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2013
Neutrophils promote the malignant glioma phenotype through S100A4Ji Liang, Yuji Piao, Lindsay Holmes, et al.
Neuro-Oncology|February 20, 2010
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and miceJohn F de Groot, Gregory Fuller, Ashok J Kumar, et al.
Pageof 13